Noradrenalin Laboratoire Aguettant (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Noradrenalin Laboratoire Aguettant, is an adrenergic agonist presented as an injectable solution for intravenous use. It is employed to raise blood pressure and improve cardiac output in patients with severe hypotension, septic shock or cardiogenic shock.

GNH USA supplies Noradrenalin Laboratoire Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Noradrenalin Laboratoire Aguettant acts as a potent vasopressor in critical‑care settings, targeting circulatory failure and shock states.

- Hypotension: restores arterial pressure to maintain organ perfusion. - Septic shock: counteracts vasodilatory failure to improve systemic vascular resistance. - Cardiogenic shock: enhances cardiac output and coronary perfusion by stimulating beta‑1 receptors.

Noradrenalin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Tachycardia: rapid heart rate due to beta‑1 stimulation. - Hypertension: excessive rise in blood pressure. - Headache: often related to vascular changes. - Nausea: gastrointestinal discomfort.

Serious or Rare Side Effects: - Myocardial ischemia: reduced coronary blood flow. - Severe hypertension: risk of vascular injury. - Life‑threatening arrhythmias: abnormal heart rhythms. - Tissue necrosis at infusion site: extravasation injury.

When using Noradrenalin, clinicians should observe several safety measures.

- Blood pressure monitoring: adjust infusion to avoid overshoot. - Cardiac rhythm surveillance: detect arrhythmias early. - Coronary artery disease caution: limit dose to prevent ischemia. - Hyperthyroidism awareness: heightened sensitivity to catecholamines. - Avoid rapid bolus: administer as controlled infusion. - Store at ambient temperature: keep in original container, protect from moisture and light.

Noradrenalin can interact with other agents that affect cardiovascular tone.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Tricyclic antidepressants: additive pressor effect. - Beta‑blockers: may blunt therapeutic response.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive episodes. - Calcium channel blockers: can alter vascular response. - ACE inhibitors: may affect blood pressure stability.